These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 8903274)

  • 21. Proarrhythmia with class III antiarrhythmic drugs: types, risks, and management.
    Hohnloser SH
    Am J Cardiol; 1997 Oct; 80(8A):82G-89G. PubMed ID: 9354415
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Amiodarone and torsades de pointes in patients with advanced heart failure.
    Middlekauff HR; Stevenson WG; Saxon LA; Stevenson LW
    Am J Cardiol; 1995 Sep; 76(7):499-502. PubMed ID: 7653452
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A benefit-risk assessment of class III antiarrhythmic agents.
    Brendorp B; Pedersen O; Torp-Pedersen C; Sahebzadah N; Køber L
    Drug Saf; 2002; 25(12):847-65. PubMed ID: 12241126
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug-induced torsade de pointes. Incidence, management and prevention.
    Faber TS; Zehender M; Just H
    Drug Saf; 1994 Dec; 11(6):463-76. PubMed ID: 7727055
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Risks and side effects in treatment of supraventricular tachycardia].
    Lüderitz B
    Z Gesamte Inn Med; 1993 Sep; 48(9):459-65. PubMed ID: 8212752
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dofetilide induced torsade de pointes: mechanism, risk factors and management strategies.
    Jaiswal A; Goldbarg S
    Indian Heart J; 2014; 66(6):640-8. PubMed ID: 25634399
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Torsades de pointes ventricular tachycardia induced by intravenous amiodarone].
    Makai A; Rudas L; Liszkai G; Fazekas T
    Orv Hetil; 2003 Feb; 144(5):241-7. PubMed ID: 12647553
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Placebo-controlled evaluations of propafenone for atrial tachyarrhythmias.
    Rae AP
    Am J Cardiol; 1998 Oct; 82(8A):59N-65N. PubMed ID: 9809902
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and proarrhythmia of oral sotalol in pediatric patients.
    Pfammatter JP; Paul T; Lehmann C; Kallfelz HC
    J Am Coll Cardiol; 1995 Oct; 26(4):1002-7. PubMed ID: 7560592
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Proarrhythmia in patients treated for atrial fibrillation or flutter.
    Falk RH
    Ann Intern Med; 1992 Jul; 117(2):141-50. PubMed ID: 1605429
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Proarrhythmia.
    Roden DM; Anderson ME
    Handb Exp Pharmacol; 2006; (171):73-97. PubMed ID: 16610341
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mechanisms and risk factors for proarrhythmia with type Ia compared with Ic antiarrhythmic drug therapy.
    Levine JH; Morganroth J; Kadish AH
    Circulation; 1989 Oct; 80(4):1063-9. PubMed ID: 2676234
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Proarrhythmia, a serious complication of antiarrhythmic drugs.
    Podrid PJ
    Curr Cardiol Rep; 1999 Nov; 1(4):289-96. PubMed ID: 10980856
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Arrhythmias and women.
    Wolbrette D; Patel H
    Curr Opin Cardiol; 1999 Jan; 14(1):36-43. PubMed ID: 9932206
    [TBL] [Abstract][Full Text] [Related]  

  • 35. "Torsade de pointes" during amiodarone infusion in a cirrhotic woman with a prolonged QT interval.
    Di Micoli A; Zambruni A; Bracci E; Benazzi B; Zappoli P; Berzigotti A; Zoli M; Bernardi M; Trevisani F
    Dig Liver Dis; 2009 Jul; 41(7):535-8. PubMed ID: 18294935
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Drug therapy of cardiac arrhythmias 199].
    Dietz A; Manz M
    Fortschr Med; 1997 Nov; 115(33):32, 34-6, 38. PubMed ID: 9480278
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and proarrhythmic hazards of pharmacologic cardioversion of atrial fibrillation: prospective comparison of sotalol versus quinidine.
    Hohnloser SH; van de Loo A; Baedeker F
    J Am Coll Cardiol; 1995 Oct; 26(4):852-8. PubMed ID: 7560608
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A consensus report on antiarrhythmic drug use.
    Reiffel JA; Estes NA; Waldo AL; Prystowsky EN; DiBianco R
    Clin Cardiol; 1994 Mar; 17(3):103-16. PubMed ID: 8168278
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Classification by type of ventricular arrhythmia predicts frequency of adverse cardiac events from flecainide.
    Morganroth J; Anderson JL; Gentzkow GD
    J Am Coll Cardiol; 1986 Sep; 8(3):607-15. PubMed ID: 3745706
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk of proarrhythmic events in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study: a multivariate analysis.
    Kaufman ES; Zimmermann PA; Wang T; Dennish GW; Barrell PD; Chandler ML; Greene HL;
    J Am Coll Cardiol; 2004 Sep; 44(6):1276-82. PubMed ID: 15364332
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.